Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
“It’s not about the poster, it’s about the timing of presenting it. Why now?”
I agree with BITL
Could it be that one of the leading BP involved with Fap is Sanofi who happens to be the main sponsor of this conference.
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
2 posters will be presented this week,
Affimer today and A3996 on Saturday.
At the last AACR in April
Avacta put out RNS at 7:00am on the morning of poster the 17th April.
Today we have a poster but No RNS
Licence deal attached later perhaps ?
GLA….
Let’s hope Avacta receive FDA feedback like this next year.
Shows how fast FDA can move a drug to market.
https://t.co/TRPPJ7VEPV
Who says MM’s are corrupt how many newbies jumped in this morning and put a stop loss on?
Must of been a few MM’s yes please we will take your shares…
Shocking
O nce
P re/Cision
T rial
I ndicates
O bliteration
N umerous
A vacta
Licensees
I nbound
T hank
Y ou
Bristol Myers Squibb said Sunday it will acquire drugmaker Mirati Therapeutics in a deal worth up to $5.8 billion, adding to its oncology business portfolio.
The company said it will pay $58 per share in cash. As part of the deal, Mirati stockholders will also receive one non-tradeable contingency value for each Mirati share held, potentially worth $12 per share in cash while representing an additional $1 billion of value opportunity, according to the announcement.
https://www.foxbusiness.com/markets/bristol-myers-squibb-buy-cancer-drugmaker-mirati-therapeutics-billion-deal.amp
They still own 50,000 Avacta shares for some reason.
Could a deal be completed this week at the AACR-NCI-EORTC International Conference.
Takeda Ventures, Inc.
Takeda Ventures, Inc. is the corporate venture capital group of Takeda, and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based investments. Takeda Ventures focuses on high-caliber, therapeutic, platform-based companies around the world.
We specifically invest in early-stage, preclinical opportunities and products which complement Takeda’s pipeline with the mission to create strategic growth opportunities for Takeda through building, managing and investing in innovative companies.
https://www.takeda.com/science/research-and-development/partnerships/cei/
GLA…..
Data rich trial
Watching the results presentation , I noticed on the slide that we all have seen plenty of times the list of cancers and their Fap concentration.
The least on this bar chart was Renal cell cancer and STS was 2nd highest Fap.
So the data rich 1a has data of AVA6000 from the least to the most Fap concentrations of cancers that is on that chart.
GLA
https://www.mskcc.org/cancer-care/clinical-trials/22-428
Truantdox
Just to rub it in.
He can’t say we are getting fast track you don’t push the fda….
Some statement:
"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.
BV
I agree if you remember he was absent from science day and AS gave his apologies
You think a science day planned for months would be a cert he attended.
The last interview on VOX with AS is the last time I can remember him being involved then since then Fiona as stepped in.
Any one who attended AGM did you see him there.
Hope he is ok
Avacta board probably kicking themselves for not taking PI’s extra cash and reducing loan borrowed or even not putting in the cash or shares clause with HCI
The sooner first licence deal arrives and we can pay HCI off the better.
Https://avacta.com/subscription-to-raise-2-million/
Wow
Kamani & Hughes
That’s 13.5 million just on todays SP from £2million outlay.
Imagine £10 T/O which is very conservative that’s
£111 million from £2 million.
Wow again
A positive outcome to this phase I study would require an improved safety profile compared with standard Doxorubicin since the efficacy of this existing chemotherapy is well known.
No wonder Avacta BOD are so positive it’s in the bag….
GLA
Don’t let the MM’s scare you into selling.
How does paradigm shift happen?
A paradigm shift—or paradigm change—happens when scientific activity and experimentation begins to contradict premises that experts previously considered unshakable. As a result, a new and different paradigm replaces the dominant paradigm of its day.
Drug Development Designations
The agency also employs several approaches to encourage the development of certain drugs, especially drugs that may represent the first available treatment for an illness, or ones that have a significant benefit over existing drugs. These approaches, or designations, are meant to address specific needs, and a new drug application may receive more than one designation, if applicable. Each designation helps ensure that therapies for serious conditions are made available to patients as soon as reviewers can conclude that their benefits justify their risks.
* Fast Track is a process designed to facilitate the development and advance the review of drugs that treat serious conditions, and fill an unmet medical need, based on promising animal or human data. Fast tracking can get important new drugs to the patient earlier. The drug company must request the Fast Track process. More information about the Fast Track process is here.
* Breakthrough Therapy designation expedites the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. A drug with Breakthrough Therapy designation is also eligible for the Fast Track process. The drug company must request a Breakthrough Therapy designation. More information about Breakthrough Therapy designation is here.
* Priority Review means that FDA aims to take action on an application within six months, compared to 10 months under standard review. A Priority Review designation directs attention and resources to evaluate drugs that would significantly improve the treatment, diagnosis, or prevention of serious conditions. More information about Priority Review is here.
https://www.fda.gov/drugs/development-approval-process-drugs
Yes but affimers are his baby, he will try and keep hold of diagnostics division.
Jmfw
2 types of affimers
Diagnostics
Affimer proteins are small, single domain binding proteins which are based on Stefin A (or Cystatin A in plants).
Therapeutics
Avacta’s proprietary Affimer technology is a novel class of small molecule entities, based on the naturally occurring human protein Stefin A, which enables the delivery of next-generation biotherapeutics.
Myles comment on twitter below.
I’m not on Twitter but would like to put my view on the diagnostic division.
The acquisitions have been rushed and I think there is a very good reason for this.
They have known for some time how good Pre/Cision is and they know it will be taken out very soon.
But once the Therapeutics division has been sold,AS and the board will not be involved with the takeover company.
So I think building up the Diagnostics division allows a split on takeover and AS still has control of his baby “Affimers” but only in diagnostics.
If this doesn’t happen AS Will be unemployed on a takeover but with millions in the bank and too young to retire and would probably start anther Biotech
Myles tweet:
I don't dislike Avacta Diagnostics; but it is the Board's first and foremost duty to protect shareholder value.
I am sure that the large majority of #AVCT holders would agree that the Coris acquisition was not in the best interests of shareholders, for the simple reason that it represented exceptionably poor decision making around capital allocation.
Launch was different; I understand that. It enabled a net cash inflow of £36m (being the £60m net fundraise proceeds, less £24m), which has been used to drive Therapeutics forward.
I am also sure that the large majority of shareholders have the same view as me, and would like to see Diagnostics sold for cash. £32m cash cost for recent two acquisitions. Let's assume a double disposal at breakeven; and, throwing in Avacta Diagnostics in Whetherby (with the Affimer platform licensed for diagnostics use only), let's round it up to £40m.
What do people think would happen to the share price if AVCT received a cash injection of £40m, with nil dilution and all preCISION assets remaining 100% owned?
The Board is acutely aware of the wishes of the large majority of shareholders, concerning this matter.
£44m left to pay on the bond
Launch Diagnostics generated £14.17 million of non-COVID-19 related revenue in FY21, with total revenues including COVID-19 related products of £32.75 million.
Coris a few more million.
Some more covid sales this year with new variant.
A year cash burn saved on P1b.
Avacta could pay down a lot of this bond before any licence deals.
GLA